Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA

Cheng,Hsueh-Tsen; Hung,Wen-Chun

doi:10.3892/or.2013.2523

Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA

Authors:
- Hsueh-Tsen Cheng
- Wen-Chun Hung
View Affiliations

Affiliations: Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, Taiwan, R.O.C., National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan, R.O.C.
Published online on: June 7, 2013 https://doi.org/10.3892/or.2013.2523
Pages: 961-967

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone deacetylase (HDAC) inhibitors exert potent inhibitory effects on various types of human cancer. The pioneer drug suberoylanilide hydroxamic acid (SAHA) is currently used in the clinic for cancer treatment. However, the effect of SAHA on tumor lymphangiogenesis is unclear. We recently showed that SAHA suppresses the expression and production of pro-lymphagenic factor vascular endothelial growth factor‑C (VEGF-C) in breast cancer cells. In the present study, the effect of SAHA on lymphatic endothelial cells (LECs) was examined. We generated a lymphatic-like endothelial cell line (named FP01) by overexpressing the master LEC transcription factor PROX1 in EA.hy926 endothelial cells. This cell line exhibited a gene expression pattern and phenotype similar to primarily cultured LECs. SAHA inhibited cell cycle progression and proliferation of FP01 cells. In addition, SAHA suppressed sprouting and tube formation in these cells. Moreover, SAHA attenuated the angiopoietin (Ang)/Tie signaling pathway which plays important roles in the regulation of LEC function. FP01 cells expressed Ang1, Ang2, Tie1 and Tie2, and SAHA dose-dependently reduced the expression of Tie2 in these cells. Tie2 promoter activity was attenuated by SAHA indicating a transcriptional repression. Importantly, Tie2 protein was significantly reduced by SAHA at the concentration in which no alteration of Tie2 mRNA was detected. We found that SAHA enhanced Tie2 protein degradation via the ubiquitin-proteasome pathway, and the expression of c-Cbl, the E3 ligase for Tie2 ubiquitination, rapidly increased after SAHA treatment. Knockdown of c-Cbl reversed SAHA‑induced Tie2 protein degradation. Taken together, our results demonstrate that SAHA impairs the proliferation, sprouting and tube formation of LECs and attenuates Ang/Tie signaling in LECs by downregulating Tie-2 via transcriptional and post-transcriptional mechanisms.

View Figures

View References

1	Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
2	Inche AG and La Thangue NB: Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov Today. 11:97–109. 2006. View Article : Google Scholar : PubMed/NCBI
3	Olsen EA, Kim YH, Kuzel TM, et al: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 25:3109–3115. 2007. View Article : Google Scholar : PubMed/NCBI
4	Duvic M and Vu J: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 16:1111–1120. 2007. View Article : Google Scholar : PubMed/NCBI
5	Emanuele S, Lauricella M and Tesoriere G: Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol. 33:637–646. 2008.PubMed/NCBI
6	Zhao Y, Tan J, Zhuang L, et al: Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA. 102:16090–16095. 2005. View Article : Google Scholar : PubMed/NCBI
7	Gui CY, Ngo L, Xu WS, et al: Histone deacetylase (HDAC) inhibitor activation of p21^WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA. 101:1241–1246. 2004. View Article : Google Scholar : PubMed/NCBI
8	Richon VM, Sandhoff TW, Rifkind RA and Marks PA: Histone deacetylase inhibitor selectively induces p21^WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 97:10014–10019. 2000. View Article : Google Scholar : PubMed/NCBI
9	Woan KV, Sahakian E, Sotomayor EM, Seto E and Villagra A: Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol. 90:55–65. 2012. View Article : Google Scholar : PubMed/NCBI
10	Blanchard F and Chipoy C: Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today. 10:197–204. 2005. View Article : Google Scholar : PubMed/NCBI
11	Deroanne CF, Bonjean K, Servotte S, et al: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 21:427–436. 2002. View Article : Google Scholar : PubMed/NCBI
12	Alitalo K: The lymphatic vasculature in disease. Nat Med. 17:1371–1380. 2011. View Article : Google Scholar : PubMed/NCBI
13	Achen MG, McColl BK and Stacker SA: Focus on lymphangiogenesis in tumor metastasis. Cancer Cell. 7:121–127. 2005. View Article : Google Scholar : PubMed/NCBI
14	Cao R, Björndahl MA, Religa P, et al: PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell. 6:333–345. 2004. View Article : Google Scholar : PubMed/NCBI
15	Augustin HG, Koh GY, Thurston G and Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 10:165–177. 2009. View Article : Google Scholar : PubMed/NCBI
16	Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
17	Yuan HT, Khankin EV, Karumanchi SA and Parikh SM: Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 29:2011–2022. 2009. View Article : Google Scholar : PubMed/NCBI
18	Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG and Koh GY: Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene. 19:4549–4552. 2000.PubMed/NCBI
19	Murray BW, Padrique ES, Pinko C and McTigue MA: Mechanistic effects of autophosphorylation on receptor tyrosine kinase catalysis: enzymatic characterization of Tie2 and phospho-Tie2. Biochemistry. 40:10243–10253. 2001. View Article : Google Scholar : PubMed/NCBI
20	Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS and Dumont DJ: A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Mol Cell Biol. 23:2658–2668. 2003. View Article : Google Scholar : PubMed/NCBI
21	Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K and Dumont DJ: Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. J Biol Chem. 274:30896–30905. 1999. View Article : Google Scholar : PubMed/NCBI
22	Dellinger M, Hunter R, Bernas M, Gale N, Yancopoulos G, Erickson R and Witte M: Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice. Dev Biol. 319:309–320. 2008. View Article : Google Scholar : PubMed/NCBI
23	Shimoda H, Bernas MJ, Witte MH, Gale NW, Yancopoulos GD and Kato S: Abnormal recruitment of periendothelial cells to lymphatic capillaries in digestive organs of angiopoietin-2-deficient mice. Cell Tissue Res. 328:329–337. 2007. View Article : Google Scholar : PubMed/NCBI
24	Kajiya K, Kidoya H, Sawane M, Matsumoto-Okazaki Y, Yamanishi H, Furuse M and Takakura N: Promotion of lymphatic integrity by angiopoietin-1/Tie2 signaling during inflammation. Am J Pathol. 180:1273–1282. 2012. View Article : Google Scholar : PubMed/NCBI
25	Pan MR, Chang TM, Chang HC, Su JL, Wang HW and Hung WC: Sumoylation of Prox1 controls its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells. J Cell Sci. 122:3358–3364. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wehrle C, Van Slyke P and Dumont DJ: Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required for internalization and degradation. Biochem J. 423:375–380. 2009. View Article : Google Scholar : PubMed/NCBI
27	Deroanne CF, Bonjean K, Servotte S, et al: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 21:427–436. 2002. View Article : Google Scholar : PubMed/NCBI
28	Ugur HC, Ramakrishna N, Bello L, et al: Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol. 83:267–275. 2007. View Article : Google Scholar : PubMed/NCBI
29	Mühlethaler-Mottet A, Meier R, Flahaut M, et al: Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer. 7:552008.PubMed/NCBI
30	Chou CW and Chen CC: HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett. 582:4059–4065. 2008. View Article : Google Scholar : PubMed/NCBI
31	Cheng HT and Hung WC: Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells. Oncol Rep. 29:1238–1244. 2013.
32	Huang H, Bhat A, Woodnutt G and Lappe R: Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 10:575–585. 2010. View Article : Google Scholar : PubMed/NCBI
33	Oliner J, Min H, Leal J, et al: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 6:507–516. 2004. View Article : Google Scholar : PubMed/NCBI
34	Shimamoto G, Gegg C, Boone T and Quéva C: Peptibodies: A flexible alternative format to antibodies. MAbs. 4:586–591. 2012. View Article : Google Scholar : PubMed/NCBI
35	Beck A and Reichert JM: Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs. 3:415–416. 2011. View Article : Google Scholar : PubMed/NCBI
36	Herbst RS, Hong D, Chap L, et al: Safety, pharmacokinetics and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 27:3557–3565. 2009. View Article : Google Scholar : PubMed/NCBI